ResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US

ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to new tariffs announced by President Trump—causing significant declines across major indexes like the Dow Jones and S&P 500—ResMed's stock remained relatively flat over the past week. The stable performance may reflect investor confidence in the potential of its innovative health solutions, contrasting with broader market volatility. While tech and consumer discretionary stocks suffered, defensive sectors saw gains, underscoring a challenging landscape for companies highly exposed to international supply chains.

Buy, Hold or Sell ResMed? View our complete analysis and fair value estimate and you decide.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Over the past five years, ResMed's total shareholder return, encompassing both share price appreciation and dividends, was 49.94%. This performance reflects the company’s successful expansion and product innovation strategies. Notably, the global rollout plans for AirSense 11 and partnerships with major tech companies could enhance its market presence, aiding the growth trajectory. The integration of SNAP technology and increased interest in sleep health have also fueled demand for its products.

In comparison to the general market, ResMed has outperformed the broader US Medical Equipment industry over the past year, underscoring its solid market positioning. Key earnings highlights include the Q1 and Q2 fiscal year 2025 results, which showed significant revenue and net income growth. Regular dividend payouts and share buybacks, such as the repurchase of 306,850 shares for US$75 million, underscore ResMed's commitment to rewarding its shareholders. These strategic actions have contributed to the company’s steady performance over the long term.

Get an in-depth perspective on ResMed's performance by reading our balance sheet health report here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com